TKPHF
Price
$29.45
Change
+$0.89 (+3.12%)
Updated
Aug 13 closing price
Capitalization
47.31B
ZTS
Price
$154.11
Change
+$1.05 (+0.69%)
Updated
Aug 15 closing price
Capitalization
68.3B
75 days until earnings call
Interact to see
Advertisement

TKPHF vs ZTS

Header iconTKPHF vs ZTS Comparison
Open Charts TKPHF vs ZTSBanner chart's image
Takeda Pharmaceutical
Price$29.45
Change+$0.89 (+3.12%)
Volume$1.33K
Capitalization47.31B
ZOETIS
Price$154.11
Change+$1.05 (+0.69%)
Volume$3.71M
Capitalization68.3B
TKPHF vs ZTS Comparison Chart in %
Loading...
TKPHF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
TKPHF vs. ZTS commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TKPHF is a StrongBuy and ZTS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (TKPHF: $29.45 vs. ZTS: $154.11)
Brand notoriety: TKPHF: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: TKPHF: 2% vs. ZTS: 106%
Market capitalization -- TKPHF: $47.31B vs. ZTS: $68.3B
TKPHF [@Pharmaceuticals: Generic] is valued at $47.31B. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $68.3B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TKPHF’s FA Score shows that 2 FA rating(s) are green whileZTS’s FA Score has 1 green FA rating(s).

  • TKPHF’s FA Score: 2 green, 3 red.
  • ZTS’s FA Score: 1 green, 4 red.
According to our system of comparison, TKPHF is a better buy in the long-term than ZTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TKPHF’s TA Score shows that 7 TA indicator(s) are bullish while ZTS’s TA Score has 6 bullish TA indicator(s).

  • TKPHF’s TA Score: 7 bullish, 3 bearish.
  • ZTS’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, ZTS is a better buy in the short-term than TKPHF.

Price Growth

TKPHF (@Pharmaceuticals: Generic) experienced а +3.11% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was +4.59% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Reported Earning Dates

ZTS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($68.3B) has a higher market cap than TKPHF($47.3B). TKPHF has higher P/E ratio than ZTS: TKPHF (50.67) vs ZTS (26.52). TKPHF YTD gains are higher at: 10.093 vs. ZTS (-4.489). TKPHF has higher annual earnings (EBITDA): 1.13T vs. ZTS (3.91B). ZTS has less debt than TKPHF: ZTS (6.75B) vs TKPHF (4.51T). TKPHF has higher revenues than ZTS: TKPHF (4.48T) vs ZTS (9.29B).
TKPHFZTSTKPHF / ZTS
Capitalization47.3B68.3B69%
EBITDA1.13T3.91B28,794%
Gain YTD10.093-4.489-225%
P/E Ratio50.6726.52191%
Revenue4.48T9.29B48,245%
Total Cash419BN/A-
Total Debt4.51T6.75B66,756%
FUNDAMENTALS RATINGS
TKPHF vs ZTS: Fundamental Ratings
TKPHF
ZTS
OUTLOOK RATING
1..100
2713
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
35
Fair valued
PROFIT vs RISK RATING
1..100
10087
SMR RATING
1..100
8719
PRICE GROWTH RATING
1..100
4760
P/E GROWTH RATING
1..100
2883
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TKPHF's Valuation (5) in the null industry is in the same range as ZTS (35) in the Pharmaceuticals Generic industry. This means that TKPHF’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's Profit vs Risk Rating (87) in the Pharmaceuticals Generic industry is in the same range as TKPHF (100) in the null industry. This means that ZTS’s stock grew similarly to TKPHF’s over the last 12 months.

ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is significantly better than the same rating for TKPHF (87) in the null industry. This means that ZTS’s stock grew significantly faster than TKPHF’s over the last 12 months.

TKPHF's Price Growth Rating (47) in the null industry is in the same range as ZTS (60) in the Pharmaceuticals Generic industry. This means that TKPHF’s stock grew similarly to ZTS’s over the last 12 months.

TKPHF's P/E Growth Rating (28) in the null industry is somewhat better than the same rating for ZTS (83) in the Pharmaceuticals Generic industry. This means that TKPHF’s stock grew somewhat faster than ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
TKPHFZTS
RSI
ODDS (%)
Bullish Trend 2 days ago
39%
Bullish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
46%
Bullish Trend 2 days ago
53%
Momentum
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
55%
MACD
ODDS (%)
Bullish Trend 2 days ago
50%
Bullish Trend 2 days ago
58%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
59%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
42%
Bullish Trend 2 days ago
58%
Advances
ODDS (%)
Bullish Trend 17 days ago
40%
Bullish Trend 2 days ago
56%
Declines
ODDS (%)
Bearish Trend 20 days ago
43%
Bearish Trend 17 days ago
56%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
53%
Bullish Trend 2 days ago
66%
Aroon
ODDS (%)
Bullish Trend 3 days ago
46%
Bearish Trend 2 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
TKPHF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NUSB25.290.02
+0.08%
Nuveen Ultra Short Income ETF
FXI38.34N/A
N/A
iShares China Large-Cap ETF
BSJR22.76N/A
N/A
Invesco BulletShares 2027 HY Corp Bd ETF
JHHY25.91-0.02
-0.10%
JHancock High Yield ETF
MSTQ37.32-0.16
-0.44%
LHA Market State™ Tactical Q ETF

TKPHF and

Correlation & Price change

A.I.dvisor tells us that TKPHF and TAK have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TKPHF and TAK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TKPHF
1D Price
Change %
TKPHF100%
N/A
TAK - TKPHF
27%
Poorly correlated
+1.35%
TEVJF - TKPHF
17%
Poorly correlated
N/A
ZTS - TKPHF
16%
Poorly correlated
+0.69%
BHC - TKPHF
15%
Poorly correlated
+11.05%
QNTM - TKPHF
13%
Poorly correlated
+0.45%
More